TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07029399: A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Sponsor: NiKang Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 361 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07029399 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07029399 Rescue Dossier →